

Anniina Färkkilä
biträdande professor, Handledare för doktorandprogram
Kvinnokliniken
Kvinnokliniken
Doctoral Programme in Integrative Life Science
Doctoral Programme in Biomedicine
Doctoral Programme in Clinical Research
HUS Kvinnosjukdomar och förlossningar
Adresstyp: Postadress.
Finland
E-post: anniina.farkkila@helsinki.fi



Kvalifikationer

Forskningsledare (Principal Investigator)
Tidsperiod : 10.12.2018 - * i Clinicum

Anställning

biträdande professor
Kvinnokliniken
Helsingfors universitet
Finland
1 maj 2023 → present

Kvinnokliniken
Helsingfors universitet
Finland
8 sep. 2010 → present

Handledare för doktorandprogram
Doctoral Programme in Integrative Life Science
Helsingfors universitet
Finland
1 jan. 2024 → present

Handledare för doktorandprogram
Doctoral Programme in Biomedicine
Helsingfors universitet
Finland
1 jan. 2014 → present

Handledare för doktorandprogram
Doctoral Programme in Clinical Research
Helsingfors universitet
Finland
1 jan. 2014 → present

HUS Kvinnosjukdomar och förlossningar
Södra Finlands samarbetsområde
Finland
1 jan. 2010 → present

Postdoctoral Fellow
Dana Farber Canc Inst, Dana Farber Cancer Center, Harvard University

Förenta Staterna (USA)

1 apr. 2017 → present

Publikationer

Insights on Future Directions in Cancer Research from the 2025 AACR NextGen Stars

Chan, E. M., Chhabra, Y., Dixon, K. O., Durbin, A. D., Färkkilä, A., Jeyasekharan, A. D., Keckesova, Z., Prensner, J. R., Wagenblast, E., Xie, S. Z. & Zhao, D., 2 apr. 2025, I: Cancer Discovery. 15, 4, s. 678-684 7 s.

Navigating life as an early career researcher

Bhatt, S., Chhabra, Y., Cohen, M., Färkkilä, A., Goel, S., Li, G. & Romero-Córdoba, S., apr. 2025, I: Trends in Cancer. 11, 4, s. 261-266 6 s.

Tribus: semi-automated discovery of cell identities and phenotypes from multiplexed imaging and proteomic data

Kang, Z., Szabo, A., Farago, T., Perez-Villatoro, F., Junquera, A., Shah, S., Launonen, I.-M., Anttila, E., Casado, J., Elias, K., Virtanen, A., Haltia, U.-M. & Färkkilä, A., 24 mars 2025, I: Bioinformatics. 41, 3, 9 s., btaf082.

Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer

Launonen, I.-M., Niemiec, I., Hincapié-Otero, M., Erkan, E. P., Junquera, A., Afenteva, D., Falco, M. M., Liang, Z., Salko, M., Chamchougia, F., Szabo, A., Perez-Villatoro, F., Li, Y., Micoli, G., Nagaraj, A., Haltia, U.-M., Kahelin, E., Oikkonen, J., Hynninen, J. & Virtanen, A. och 6 andra, Nirmal, A. J., Vallius, T., Hautaniemi, S., Sorger, P. K., Vähärautio, A. & Färkkilä, A., 9 dec. 2024, I: Cancer Cell. 42, 12, s. 2045-2063.e10 29 s.

Mathematical modeling framework enhances clinical trial design for maintenance treatment in oncology

Kozłowska, E., Haltia, U.-M., Puszynski, K. & Färkkilä, A., 29 nov. 2024, I: Scientific Reports. 14, 1, 11 s., 29721.

Randomized Phase II Study of Gemcitabine with or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses

Konstantinopoulos, P. A., Cheng, S. C., Lee, E. K., Da Costa, A. A. B. A., Gulhan, D., Wahner Hendrickson, A. E., Kochupurakkal, B., Kolin, D. L., Kohn, E. C., Liu, J. F., Penson, R. T., Stover, E. H., Curtis, J., Sawyer, H., Polak, M., Chowdhury, D., D'Andrea, A. D., Färkkilä, A., Shapiro, G. I. & Matulonis, U. A., 1 apr. 2024, I: JCO Precision Oncology. 8, 12 s., e2300635.

Abstract A103: Improved cell phenotyping of ovarian cancer tumor microenvironment

Kang, Z., Faragó, T., Szabó, A., Launonen, I.-M. P., Perez Villatoro, F. R., Anttila, E., Elias, K. M., Casado, J., Sorger, P. K. & Färkkilä, A., 4 mars 2024.

Tracing back primed resistance in cancer via sister cells

Dai, J., Zheng, S., Falco, M. M., Bao, J., Eriksson, J., Pikkusaari, S., Forstén, S., Jiang, J., Wang, W., Gao, L., Perez-Villatoro, F., Dufva, O., Saeed, K., Wang, Y., Amiryousefi, A., Färkkilä, A., Mustjoki, S., Kauppi, L., Tang, J. & Vähärautio, A., 7 feb. 2024, I: Nature Communications. 15, 1, 14 s., 1158.

Gynekologiset syövät

Färkkilä, A., 2024, *Syöpäsairaudet*. Leppä, S., Jyrkkiö, S., Pasanen, A., Pitkaniemi, J., Puolakkainen, P., Tenhunen, O. & Vaalavirta, L. (red.). 1. p. red. Helsinki: Duodecim, s. 332-356 25 s.

Kohdunrunkosyövän tarkentuva diagnostiikka ja hoito - immuno-onkologiset hoidot tuovat uutta toivoa

Färkkilä, A., Haltia, U.-M., Pasanen, A. & Lassus, H., 2024, I: Duodecim. 140, 19, s. 1633-1639 7 s.

Dysregulated germinal centre reaction with expanded T follicular helper cells in APECED lymph nodes

Hetemäki, I., Sarkkinen, J., Heikkilä, N., Drechsel, K., Mäyränpää, M. I., Färkkilä, A., Laakso, S., Mäkitie, O., Arstila, T. P. & Kekäläinen, E., 19 dec. 2023, I: Journal of Allergy and Clinical Immunology. 153, 5, s. 1445-1455 11 s.

The Emerging Role of the Single-Cell and Spatial Tumor Microenvironment in High-Grade Serous Ovarian Cancer

Launonen, I.-M., Vähärautio, A. & Färkkilä, A., okt. 2023, I: Cold Spring Harbor Perspectives in Medicine. 13, 10, 9 s., a041314.

Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

Pikkusaari, S., Tumiat, M., Virtanen, A., Oikonen, J., Li, Y., Perez-Villatoro, F., Muranen, T., Salko, M., Huhtinen, K., Kanerva, A., Koskela, H., Tapper, J., Koivisto-Korander, R., Joutsiniemi, T., Haltia, U.-M., Lassus, H., Hautaniemi, S., Färkkilä, A., Hynninen, J. & Hietanen, S. och 2 andra, Carpen, O. & Kauppi, L., 15 aug. 2023, I: Clinical Cancer Research. 29, 16, s. 3110-3123 14 s.

Uusi työkalu räätälöityyn munasarjasyövän hoitoon

Pikkusaari, S., Tumiat, M., Virtanen, A., Oikonen, J., Li, Y., Perez-Villatoro, F., Muranen, T., Salko, M., Huhtinen, K., Kanerva, A., Koskela, H., Tapper, J., Koivisto-Korander, R., Joutsiniemi, T., Haltia, U.-M., Lassus, H., Hautaniemi, S., Färkkilä, A., Hynninen, J. & Hietanen, S. och 2 andra, Carpen, O. & Kauppi, L., 15 aug. 2023, I: Duodecim. 139, 9, s. 760 1 s.

STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer

Ding, L., Wang, Q., Martincuks, A., Kearns, M. J., Jiang, T., Lin, Z., Cheng, X., Qian, C., Xie, S., Kim, H.-J., Launonen, I.-M., Färkkilä, A., Roberts, T. M., Freeman, G. J., Liu, J. F., Konstantinopoulos, P. A., Matulonis, U., Yu, H. & Zhao, J. J., jan. 2023, I: Journal for Immunotherapy of Cancer. 11, 1, 15 s., e005627.

Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer

Launonen, I.-M., Lyytikäinen, N., Casado, J., Anttila, E. A., Szabo, A., Haltia, U.-M., Jacobson, C. A., Lin, J. R., Maliga, Z., Howitt, B. E., Strickland, K. C., Santagata, S., Elias, K., D'Andrea, A. D., Konstantinopoulos, P. A., Sorger, P. K. & Färkkilä, A., dec. 2022, I: Nature Communications. 13, 1, 14 s., 835.

Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer

Chae, C. S., Sandoval, T. A., Hwang, S. M., Park, E. S., Giovanelli, P., Awasthi, D., Salvagno, C., Emmanuelli, A., Tan, C., Chaudhary, V., Casado, J., Kossenkova, A. V., Song, M., Barrat, F. J., Holcomb, K., Romero-Sandoval, E. A., Zamarin, D., Pépin, D., D'Andrea, A. D. & Färkkilä, A. och 1 andra, Cubillos-Ruiz, J. R., 1 aug. 2022, I: Cancer Discovery. 12, 8, s. 1904-1921 18 s.

Analysis of Non-Relapsed and Relapsed Adult Type Granulosa Cell Tumors Suggests Stable Transcriptomes during Tumor Progression

Andersson, N., Haltia, U.-M., Färkkilä, A., Wong, S. C., Eloranta, K., Wilson, D. B., Unkila-Kallio, L., Pihlajoki, M., Kyrölähti, A. & Heikinheimo, M., feb. 2022, I: Current Issues in Molecular Biology. 44, 2, s. 686-698 13 s.

Munasarjasyövän immuunipuolustukselta piiloutumisen mekanismit paljastuvat

Launonen, I.-M., Lyytikäinen, N., Casado, J., Anttila, E., Szabo, A., Haltia, U.-M., Jacobson, C. A., Lin, J.-R., Maliga, Z., Howitt, B., Strickland, K., Santagata, S., Elias, K., D'Andrea, A., Konstantinopoulos, P., Sorger, P. & Färkkilä, A., 2022, I: Duodecim. 138, 5, s. 455 1 s.

Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer

Perez Villatoro, F. R., Oikonen, J., Casado, J., Chernenko, A., Gulhan, D. C., Tumiat, M., Li, Y., Lavikka, K. A., Hietanen, S., Hynninen, J., Haltia, U.-M., Tyrmi, J. S., Laivuori, H., Konstantinopoulos, P. A., Hautaniemi, S., Kauppi, L. & Färkkilä, A., 2022, I: npj precision oncology. 6, 1, 13 s., 96.

Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation

Duraiswamy, J., Turrini, R., Minasyan, A., Barras, D., Crespo, I., Grimm, A. J., Casado, J., Genolet, R., Benedetti, F., Wicky, A., Ioannidou, K., Castro, W., Neal, C., Moriot, A., Renaud-Tissot, S., Anstett, V., Fahr, N., Tanyi, J. L., Eiva, M. A. & Jacobson, C. A. och 16 andra, Montone, K. T., Westergaard, M. C. W., Svane, I. M., Kandalaft, L. E., Delorenzi, M., Sorger, P. K., Färkkilä, A., Michielin, O., Zoete, V., Carmona, S. J., Foukas, P. G., Jr, D. J. P., Rusakiewicz, S., Doucey, M.-A., Laniti, D. D. & Coukos, G., 13 dec. 2021, I: Cancer Cell. 39, 12, s. 1623-+ 41 s.

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

Konstantinopoulos, P. A., da Costa, A. A. B. A., Gulhan, D., Lee, E. K., Cheng, S.-C., Hendrickson, A. E. W., Kochupurakkal, B., Kolin, D. L., Kohn, E. C., Liu, J. F., Stover, E. H., Curtis, J., Tayob, N., Polak, M., Chowdhury, D., Matulonis, U. A., Färkkilä, A., D'Andrea, A. D. & Shapiro, G., 22 sep. 2021, I: Nature Communications. 12, 1, 8 s., 5574.

Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells

Färkkilä, A., Rodriguez, A., Oikonen, J., Gulhan, D. C., Huy Nguyen, Dominguez, J., Ramos, S., Mills, C. E., Perez-Villatoro, F., Lazaro, J.-B., Zhou, J., Clairmont, C. S., Moreau, L. A., Park, P. J., Sorger, P. K., Hautaniemi, S., Frias, S. & D'Andrea, A. D., 15 maj 2021, I: Cancer Research. 81, 10, s. 2774-2787 14 s.

Agile workflow for interactive analysis of mass cytometry data

Casado, J., Lehtonen, O., Rantanen, V., Kaipio, K., Pasquini, L., Häkkinen, A., Petrucci, E., Hynninen, J., Hietanen, S., Carpen, O., Biffoni, M., Färkkilä, A. & Hautaniemi, S., 1 maj 2021, I: Bioinformatics. 37, 9, s. 1263-1268 6 s.

Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease

Pilsworth, J. A., Cochrane, D. R., Neilson, S. J., Moussavi, B. H., Lai, D., Munzur, A. D., Senz, J., Wang, Y. K., Zareian, S., Bashashati, A., Wong, A., Keul, J., Staebler, A., van Meurs, H. S., Horlings, H. M., Kommoss, S., Kommoss, F., Oliva, E., Färkkilä, A. E. M. & Gilks, B. och 1 andra, Huntsman, D. G., maj 2021, I: The Journal of Pathology. Clinical Research. 7, 3, s. 243-252 10 s.

Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro

Crosley, P., Farkkila, A., Jenner, A., Burlot, C., Cardinal, O., Potts, K., Agopsowicz, K., Pihlajoki, M., Heikinheimo, M., Craig, M., Fu, Y. & Hitt, M., maj 2021, I: International Journal of Molecular Sciences. 22, 9, 17 s., 4699.

Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy

Iyer, S., Zhang, S., Yucel, S., Horn, H., Smith, S. G., Reinhardt, F., Hoefsmit, E., Assatova, B., Casado, J., Meinsohn, M.-C., Barrasa, M. I., Bell, G. W., Perez-Villatoro, F., Huhtinen, K., Hynninen, J., Oikonen, J., Galhenage, P. M., Pathania, S., Hammond, P. T. & Neel, B. G. och 3 andra, Farkkila, A., Pepin, D. & Weinberg, R. A., feb. 2021, I: Cancer Discovery. 11, 2, s. 384-407 24 s.

MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia

Rodriguez, A., Zhang, K., Färkkilä, A., Filiatrault, J., Yang, C., Velazquez, M., Furutani, E., Goldman, D. C., Garcia de Teresa, B., Garza-Mayen, G., McQueen, K., Sambel, L. A., Molina, B., Torres, L., Gonzalez, M., Vadillo, E., Pelayo, R., Fleming, W. H., Grompe, M. & Shimamura, A. och 5 andra, Hautaniemi, S., Greenberger, J., Frias, S., Parmar, K. & D'Andrea, A. D., 7 jan. 2021, I: Cell Stem Cell. 28, 1, s. 33-+ 23 s.

Inhibition of TGF beta 1 and TGF beta 3 promotes hematopoiesis in Fanconi anemia

Rodriguez, A., Yang, C., Furutani, E., Teresa, B. G. D., Velazquez, M., Filiatrault, J., Sambel, L. A., Phan, T., Flores-Guzman, P., Sanchez, S., Orozco, A. M., Mayani, H., Bolukbasi, O. V., Färkkilä, A., Epperly, M., Greenberger, J., Shimamura, A., Frias, S., Grompe, M. & Parmar, K. och 1 andra, D'Andrea, A. D., jan. 2021, I: Experimental Hematology. 93, s. 70-U53 19 s.

DNA-vaurioiden hyödyntäminen munasarjasyövän hoidossa

Färkkilä, A., Launonen, I.-M., Perez, F., Virtanen, A. & Lassus, H., 2021, I: Duodecim. 137, 21, s. 2287-2295 9 s.

PARP:n estäjät mullistavat munasarjasyövän hoidon : hoidosta eniten hyötyvät voidaan tunnistaa geneettisen testauksen avulla

Färkkilä, A., Lassus, H. & Loukovaara, M., 2021, I: Duodecim. 137, 21, s. 2228-2230 3 s.

Functional Profiling of FSH and Estradiol in Ovarian Granulosa Cell Tumors

Haltia, U.-M., Pihlajoki, M., Andersson, N., Mäkinen, L., Tapper, J., Cervera, A., Horlings, H. M., Turpeinen, U., Anttonen, M., Bützow, R., Unkila-Kallio, L., Carpen, O., Wilson, D. B., Heikinheimo, M. & Färkkilä, A., apr. 2020, I: Journal of the Endocrine Society. 4, 4, 20 s., 034.

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

Färkkilä, A., Gulhan, D. C., Casado, J., Jacobson, C. A., Nguyen, H., Kochupurakkal, B., Maliga, Z., Yapp, C., Chen, Y.-A., Schapiro, D., Zhou, Y., Graham, J. R., Dezube, B. J., Munster, P., Santagata, S., Garcia, E., Rodig, S., Lako, A., Chowdhury, D. & Shapiro, G. och 7 andra, Matulonis, U. A., Park, P. J., Hautaniemi, S., Sorger, P. K., Swisher, E. M., D'Andrea, A. D. & Konstantinopoulos, P. A., 19 mars 2020, I: Nature Communications. 11, 1, 13 s., 1459.

Virtual clinical trials identify effective combination therapies in ovarian cancer

Kozłowska, E., Vallius, T., Hynninen, J., Hietanen, S., Färkkilä, A. & Hautaniemi, S., 10 dec. 2019, I: Scientific Reports. 9, 9 s., 18678.

Open Source Infrastructure for Health Care Data Integration and Machine Learning Analyses

Isoviita, V.-M., Salminen, L., Azar, J., Lehtonen, R., Roering, P., Carpen, O., Hietanen, S., Grénman, S., Hynninen, J., Färkkilä, A. & Hautaniemi, S., 27 aug. 2019, I: JCO Clinical Cancer Informatics. 3, 16 s.

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

Konstantinopoulos, P. A., Waggoner, S., Vidal, G. A., Mita, M., Moroney, J. W., Holloway, R., Van Le, L., Sachdev, J. C., Chapman-Davis, E., Colon-Otero, G., Penson, R. T., Matulonis, U. A., Kim, Y. B., Moore, K. N., Swisher, E. M., Färkkilä, A., D'Andrea, A., Stringer-Reasor, E., Wang, J. & Buerstatte, N. och 5 andra, Arora, S., Graham, J. R., Bobilev, D., Dezube, B. J. & Munster, P., aug. 2019, I: JAMA Oncology. 5, 8, s. 1141-1149 9 s.

Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer

Oikonen, J., Zhang, K., Salminen, L., Schulman, I., Lavikka, K., Andersson, N., Ojanperä, E., Hietanen, S., Grénman, S., Lehtonen, R., Huhtinen, K., Carpen, O., Hynninen, J., Färkkilä, A. & Hautaniemi, S., 3 maj 2019, I: JCO Precision Oncology. 3, 3, s. 1-12 12 s.

Evaluation of risk factors for oral infection with potential for spread in a 1-year cohort study

Färkkilä, E., Rautemaa-Richardson, R., Färkkilä, A., Grönholm, L. & Lauhio, A., feb. 2019, I: Clinical Oral Investigations. 23, 2, s. 905-911 7 s.

Other Primary Malignancies Among Women With Adult-Type Ovarian Granulosa Cell Tumors

Bryk, S., Pukkala, E., Färkkilä, A., Heikinheimo, M., Unkila-Kallio, L. & Riska, A., okt. 2018, I: International Journal of Gynecological Cancer. 28, 8, s. 1529-1534 6 s.

A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients

Tumati, M., Hietanen, S., Hynninen, J., Pietilä, E., Färkkilä, A., Kaipio, K., Roering, P., Huhtinen, K., Alkods, A., Li, Y., Lehtonen, R., Erkan, E. P., Tuominen, M. M., Lehti, K., Hautaniemi, S. K., Vähärautio, A., Grenman, S., Carpen, O. & Kauppi, L., 15 sep. 2018, I: Clinical Cancer Research. 24, 18, s. 4482-4493 12 s.

Mathematical Modeling Predicts Response to Chemotherapy and Drug Combinations in Ovarian Cancer

Kozłowska, E., Färkkilä, A., Vallius, T., Carpen, O., Kempainen, J., Grenman, S., Lehtonen, R., Hynninen, J., Hietanen, S. & Hautaniemi, S., 15 juli 2018, I: Cancer Research. 78, 14, s. 4036-4044 9 s.

TERT promoter mutation in adult granulosa cell tumor of the ovary

Pilsworth, J. A., Cochrane, D. R., Xia, Z., Aubert, G., Färkkilä, A. E. M., Horlings, H. M., Yanagida, S., Yang, W., Lim, J. L. P., Wang, Y. K., Bashashati, A., Keul, J., Wong, A., Norris, K., Brucker, S. Y., Taran, F.-A., Krämer, B., Staebler, A., van Meurs, H. & Oliva, E. och 6 andra, Shah, S. P., Kommoss, S., Kommoss, F., Gilks, C. B., Baird, D. M. & Huntsman, D. G., juli 2018, I: Modern Pathology. 31, 7, s. 1107-1115 9 s.

Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells

Haltia, U.-M., Andersson, N., Yadav, B., Färkkilä, A., Kuleskiy, E., Kankainen, M., Tang, J., Butzow, R., Riska, A., Leminen, A., Heikinheimo, M., Kallioniemi, O., Unkila-Kallio, L., Wennerberg, K., Aittokallio, T. & Anttonen, M., mars 2017, I: Gynecologic Oncology. 144, 3, s. 621-630 10 s.

FOXL2 402C > G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor

Färkkilä, A., McConechy, M. K., Yang, W., Talhouk, A., Ng, Y., Lum, A., Morin, R. D., Bushell, K., Riska, A., McAlpine, J. N., Gilks, C. B., Unkila-Kallio, L., Anttonen, M. & Huntsman, D. G., jan. 2017, I: Journal of Molecular Diagnostics. 19, 1, s. 126-136 11 s.

Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Mullerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors

Haltia, U.-M., Hallamaa, M., Tapper, J., Hynninen, J., Alfthan, H., Kalra, B., Ritvos, O., Heikinheimo, M., Unkila-Kallio, L., Perheentupa, A. & Farkkila, A., jan. 2017, I: Gynecologic Oncology. 144, 1, s. 83-89 7 s.

Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary

Farkkila, A., Haltia, U.-M., Tapper, J., McConechy, M. K., Huntsman, D. G. & Heikinheimo, M., 2017, I: Annals of Medicine. 49, 5, s. 435-447 13 s.

Characteristics and outcome of recurrence in molecularly defined adult-type ovarian granulosa cell tumors

Bryk, S. S., Färkkilä, A., Butzow, R., Leminen, A., Johanna, T., Heikinheimo, M., Unkila-Kallio, L. & Riska, A., dec. 2016, I: Gynecologic Oncology. 143, 3, s. 571-577 7 s.

Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype

McConechy, M. K., Farkkila, A., Horlings, H. M., Talhouk, A., Unkila-Kallio, L., van Meurs, H. S., Yang, W., Rozenberg, N., Andersson, N., Zaby, K., Bryk, S., Butzow, R., Halfwerk, J. B. G., Hooijer, G. K. J., van de Vijver, M. J., Buist, M. R., Kenter, G. G., Brucker, S. Y., Kramer, B. & Staebler, A. och 6 andra, Bleeker, M. C. G., Heikinheimo, M., Kommoss, S., Gilks, C. B., Anttonen, M. & Huntsman, D. G., nov. 2016, I: Journal of the National Cancer Institute. 108, 11, 5 s., 134.

Circulating levels of TNF-related apoptosis inducing-ligand are decreased in patients with large adult-type granulosa cell tumors-implications for therapeutic potential

Farkkila, A., Zauli, G., Haltia, U.-M., Pihlajoki, M., Unkila-Kallio, L., Secchiero, P. & Heikinheimo, M., sep. 2016, I: Tumor Biology. 37, 9, s. 11909-11916 8 s.

GATA factors in endocrine neoplasia

Pihlajoki, M., Farkkila, A., Soini, T., Heikinheimo, M. & Wilson, D. B., feb. 2016, I: Molecular and Cellular Endocrinology. 421, C, s. 2-17 16 s.

Munasarjan granuloosisolukasvaimen diagnostiikka ja seuranta tarkentuvat

Färkkilä, A. & Unkila-Kallio, L., 2016, I: Duodecim. 132, 11, s. 1033-1039 7 s.

Toisen raskauskolmanneksen samanaikainen kohdunulkoinen ja -sisäinen raskaus on vakava raskauskomplikaatio

Färkkilä, A. & Laitinen, L., 2016, I: Duodecim. 132, 8, s. 730-733 4 s.

The clinical utility of serum anti-Mullerian hormone in the follow-up of ovarian adult-type granulosa cell tumorsA comparative study with inhibin B

Farkkila, A., Koskela, S., Bryk, S., Alfthan, H., Butzow, R., Leminen, A., Puistola, U., Tapanainen, J. S., Heikinheimo, M., Anttonen, M. & Unkila-Kallio, L., 1 okt. 2015, I: International Journal of Cancer. 137, 7, s. 1661-1671 11 s.

Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: a 56-year single-center experience.

Bryk, S. S., Färkkilä, A., Butzow, R., Anttonen, M., Heikinheimo, M., Leminen, A., Riska, A. & Unkila-Kallio, L., 25 jan. 2015, I: International Journal of Gynecological Cancer. 25, 1, s. 33-41 9 s.

Sensitivity of human granulosa cell tumor cells to epidermal growth factor receptor inhibition

Andersson, N., Anttonen, M., Farkkila, A., Pihlajoki, M., Butzow, R., Unkila-Kallio, L. & Heikinheimo, M., apr. 2014, I: Journal of Molecular Endocrinology. 52, 2, s. 223-234 12 s.

FOXJ2, GATA4, and SMAD3 Co-Operatively Modulate Gene Expression, Cell Viability and Apoptosis in Ovarian Granulosa Cell Tumor Cells

Anttonen, M., Pihlajoki, M., Andersson, N., Georges, A., L'Hote, D., Vattulainen, S., Farkkila, A., Unkila-Kallio, L., Veitia, R. A. & Heikinheimo, M., 9 jan. 2014, I: PLoS One. 9, 1, 8 s., 85545.

HER2 and GATA4 are new prognostic factors for early-stage ovarian granulosa cell tumor-a long-term follow-up study
Färkkilä, A., Andersson, N. K., Butzow, R., Leminen, A., Heikinheimo, M., Anttonen, M. & Unkila-Kallio, L., 2014, I: Cancer medicine . 3, 3, s. 526-536 11 s.

Seerumin anti-Müllerin hormonin (AMHn) kliininen käyttö : lisääntymisestä granuloosasolukasvaimiin
Färkkilä, A. & Anttonen, M., 2014, I: Klin lab : kliinisen laboratorioalan julkaisu : SKKY:n jäsenlehti.. 31, 3, s. 36-39 4 s.

Klinisk användning av serum Anti-Müllerskt Hormon (AMH): Från reproduktion till granulosa celltumörer
Färkkilä, A. & Anttonen, M., 2012, I: Klinisk biokemi i Norden.. 24, 1, s. 50-54 5 s.

Molecular studies on pathogenesis, prognostic factors, and new treatment options for ovarian granulosa cell tumors
Färkkilä, A., 2012, Helsinki: [A. Färkkilä]. 80 s.

Anti-Mullerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis
Anttonen, M., Färkkilä, A., Tauriala, H., Kauppinen, M., MacLaughlin, D. T., Unkila-Kallio, L., Butzow, R. & Heikinheimo, M., 2011, I: Laboratory Investigation. 91, 11, s. 1605-1614 10 s.

Serum Vascular Endothelial Growth Factor A (VEGF) Is Elevated in Patients with Ovarian Granulosa Cell Tumor (GCT), and VEGF Inhibition by Bevacizumab Induces Apoptosis in GCT in Vitro
Farkkila, A., Pihlajoki, M., Tauriala, H., Butzow, R., Leminen, A., Unkila-Kallio, L., Heikinheimo, M. & Anttonen, M., 2011, I: Journal of Clinical Endocrinology and Metabolism. 96, 12, s. E1973-E1981 9 s.

Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors
Färkkilä, A., Anttonen, M. T., Pociuviene, J., Leminen, A., Butzow, R., Heikinheimo, M. & Unkila-Kallio, L., 2011, I: European Journal of Endocrinology. 164, 1, s. 115-122 8 s.

Vascular endothelial growth factor-C accelerates diabetic wound healing
Saaristo, A., Tammela, T., Färkkilä, A., Kärkkäinen, M., Suominen, E., Ylä-Herttuala, S. & Alitalo, K., 2006, I: The American Journal of Pathology. 169, 3, s. 1080-1087 8 s.

Priser

Eero Saksela palkinto
Färkkilä, A. (!!Recipient), 23 sep. 2022

Seth Wichmann palkinto
Färkkilä, A. (!!Recipient), 15 nov. 2018

Projekt

Discovery and therapeutic exploitation of immunological vulnerabilities in high grade serous ovarian cancer
Färkkilä, A. (Projektledare)
01/01/2019 → ...

Discovery and therapeutic exploitation of immunological vulnerabilities in ovarian cancer
Färkkilä, A. (Projektledare), Kang, Z. (Deltagare), Niemiec, I. (Deltagare), Nagaraj, A. (Deltagare), Perez Villatoro, F. R. (Deltagare), Chernenko, A. (Deltagare) & Shah, S. (Deltagare)
01/01/2021 → 31/12/2023

Discovery and therapeutic exploitation of immunological vulnerabilities in ovarian cancer
Färkkilä, A. (Projektledare), Casado, J. (Deltagare), Perez Villatoro, F. R. (Deltagare), Pietilä, E. (Deltagare), Nagaraj, A. (Deltagare) & Launonen, I.-M. P. (Deltagare)

SUOMEN AKATEMIA
01/01/2021 → 31/12/2024

EU_ERC_Färkkilä Anniina_Space_101076096

Färkkilä, A. (Projektledare), Chernenko, A. (deltagare), Hincapie Otero, M. M. (deltagare), Junquera Mencía, A. (deltagare), Kaislo, V. E. E. (deltagare), Kang, Z. (deltagare), Niemiec, I. (deltagare), Palomino Echeverria, S. (deltagare), Perez Villatoro, F. R. (deltagare), Ruuska, E. A. (deltagare) & Shah, S. (deltagare)
European Commision Joint Research Centre
01/02/2023 → 31/01/2028

Munasarjasyöväen täsmälääketiede immunogenomisen profiiloinnin avulla

Färkkilä, A. (Projektledare), Elomaa, H. K. (deltagare), Jukonen, J. J. J. (deltagare), Nagaraj, A. (deltagare), Perez Villatoro, F. R. (deltagare) & Shah, S. (deltagare)
Suomen Akatemia Projektilaskutus
01/09/2022 → 31/08/2026

Syöpäsäätiö 2024-26_Färkkilä

Färkkilä, A. (Projektledare) & Szabó, A. (deltagare)
Syöpäsäätiö sr Cancerstiftelsen sr
01/01/2024 → 31/12/2026

SELECTED INTERNATIONAL INVITED TALKS

09/2021AACR Virtual special conference: Ovarian cancer 2021
04/2021University of Minnesota Department of Pharmacology Spring seminar 2021 (virtual)
03/2021Annual meeting 2021, NSGO, Copenhagen, Denmark (virtual)
06/2020Ludwig meeting, The Ludwig Center of Harvard Medical School, Boston, USA
01/2020Annual meeting, Stand Up to Cancer, Santa Monica, CA, USA
11/2019Annual meeting 2019, Mexican society of Human Genetics, Tuxtla, Chiapas, Mexico
06/2019Annual meeting 2019, British Society for Gynecologic Oncology, Cambridge, UK
06/2016Annual meeting 2016, Nordic Federation of Obstetrics and Gynecologists, Helsinki, Finland
ORGANISATION OF SCIENTIFIC MEETINGS (as a Coordinator)
23.08.2021Special seminar on Highly Multiplexed imaging and Spatial proteomics, UH and HUH
2019 - Bioimaging Informatics working group, monthly seminars, ONCOSYS Research Program, HUH
18.11.2020Advances in the treatment of Gynecologic cancers 2020, Virtual Symposium, UH and HUH
18.11.2019Biomedicum Helsinki invited lecturer Professor David Huntsman, Vancouver, BC, Canada
26.08.2019Advances in Precision Oncology and Biomarkers in Clinical Trials Symposium, UH and HUH
26.01.2017Clinical data- workshop, Hercules EU consortium

INSTITUTIONAL RESPONSIBILITIES

2021-Student mentor for MD-PhD program, UH, Finland
09/2021Official PhD Opponent, University of Bergen, Norway
2022Thesis committee, Santeri Pekola, B.Med
2021Thesis committee, Essi Friman, MD
2020Thesis committee, Michaela Feodoroff, M.Sc
2020Thesis committee, Wafa Wahbi, M.Sc
2020Thesis committee, Petra Nygren, B.Med
2019Thesis committee, Sara Khamaiseh, M.Sc
2016Pre-examiner, Susanna Jonkka M.Sc, Master's Thesis
2016 - 2020Thesis committee, Liina Salminen MD
2015Thesis committee, Jaana Tolvanen M.Sc
2015Thesis committee, Elina Pietilä M.Sc
2016Pre-examiner, Susanna Jonkka M.Sc, Master's Thesis, UH, Finland

EXPERT PANELS AND REVIEWING ACTIVITY

2021 - Board member, European Network of gynecological clinical trials (ENTOG) and Gynecologic Cancer Inter Group (GCIG)
2021 - Board member, Finnish Cancer Center (FICAN) National Molecular tumor board
2021 - Board member, GSK Advisory Board "Evolving Role of Homologous Recombination Deficiency (HRD) Testing in the Treatment of Ovarian Cancer"
2020 - Board member, Translational working group, Nordic Society for Gynecologic Oncology (NSGO) Clinical trials unit
2020 - Consortium member, Nordic consortium for HRD biomarker development
2020Review panel member, National Autonomous University of Mexico, Mexico
2019 - Board member, Ethical board, Helsinki University Hospital, Helsinki, Finland
2015- Reviewer for 15 scientific journals such as Nature, Annals of Oncology Nature Communications, Cancer Research,

International Journal of Cancer, Gynecologic Oncology, Cancers

MAJOR COLLABORATIONS

George Coukos Functional states of tumor-infiltrating lymphocytes in high-grade serous ovarian cancer. University of Lausanne, Lausanne, Switzerland

Robert Weinberg Immune microenvironments and therapeutic vulnerabilities of novel syngeneic mouse models of ovarian cancer. Whitehead Institute, Boston, MA, USA

David Huntsman Molecular diagnostics of ovarian granulosa cell tumors. University of British Columbia, Vancouver, BC, Canada

CAREER BREAKS

01.12.2009 - 31.8.2010 Maternity leave (9 months)

10.08.2012 - 31.4.2013 Maternity leave (9 months)